Predictive Technology Group Names Jay M. Moyes To Its Board Of Directors
30-year healthcare veteran brings considerable financial and governance expertise
Salt Lake City (February 28, 2019) — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Jay M. Moyes has been named to the company’s Board as an independent director, effective immediately. Moyes brings more than 30 years of healthcare industry expertise in senior-level financial positions and has significant governance experience from Board memberships at publicly traded healthcare companies. His appointment expands Predictive’s Board to five.
“We are delighted to attract a professional of Jay’s caliber as we build out Predictive’s Board with proven leaders to support our strategy of bringing proprietary genetic-based diagnostics and therapeutics to market,” said Bradley C. Robinson, CEO of Predictive Technology Group. “Jay’s extensive financial background in companies spanning from development-stage to commercial operations in diagnostics, genetics and therapeutics makes him ideally suited for this role. His wealth of governance experience from many years on multiple healthcare Boards will be particularly valuable, and we are excited to welcome Jay to our Board.”
“I’m delighted to join this company on the cutting-edge of precision medicine,” said Moyes. “Predictive’s approach to using proprietary, extensive genetic data analytics to bring novel diagnostics and therapeutics to underserved markets in women’s health and spinal disease positions it to make important contributions to improving health care. I look forward to working toward achieving the company’s goals.”
Moyes previously served as Chief Financial Officer and Director of the publicly traded biomaterials company Amedica Corporation, now SINTX Technologies, where he managed the company’s IPO and listing on NASDAQ, and as Chief Financial Officer at publicly traded CareDx, a molecular diagnostics company where he introduced a strategy to reach profitability. Prior to that he held senior finance positions including Chief Financial Officer during his 14-year tenure at publicly traded Myriad Genetics. In addition to overseeing all financial aspects at Myriad as the company transitioned from 10 to more than 900 employees, he was instrumental in raising more than $500 million in public and private financings. He previously was Vice President of Finance and Chief Financial Officer of Genmark, a private genetics company. Moyes began his career in public accounting at KPMG.
Moyes serves on the Boards of Directors of Achieve Life Sciences (NASDAQ: ACHV), BioCardia (OTC/QB: BCDA) and Puma Biotechnologies (NYSE: PBYI). In addition to Amedica, he previously was a director and Chairman of the Audit Committee of both Osiris Therapeutics (NASDAQ: OSIR) and Integrated Diagnostics. He also served as a member of the Board of Trustees of the Utah Life Science Association. Moyes holds a BA in economics from Weber State University and an MBA from the University of Utah.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com and Predictivebiotech.com.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.